A Comparison of the Acute Antiemetic Effect of Tropisetron with Ondansetron in Patients Receiving Cisplatin.
- Author:
Sung Tae CHO
1
;
Bo Kwon HWANG
;
Chan Kyu KIM
;
Bong Min KO
;
Sung Han BAE
;
Jong Dae BONG
;
Cheol Woo LEE
;
Sung Kyu PARK
;
Jong Ho WON
;
Seung Ho BAICK
;
Dae Sik HONG
;
Hee Sook PARK
Author Information
1. Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Tropisetron;
Ondansetron;
Cisplatin;
Emesis
- MeSH:
Antiemetics*;
Appetite;
Cisplatin*;
Cross-Over Studies;
Dexamethasone;
Drug Therapy;
Half-Life;
Headache;
Humans;
Nausea;
Ondansetron*;
Vomiting
- From:Journal of the Korean Cancer Association
1998;30(6):1240-1248
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Tropisetron, a new specific 5-hydroxytryptamine3 (5-HT3) receptor antagonist, is an effective antiemetic agent in the control of chemotherapy induced emesis with a long half life and bioavailablity. We compared the efficacy and safefy of Tropisetron and ondansetron to control emesis induced by highly emetogenic chemotherapeutics (cisplatin > or = 50 mg/m(2)). MATERIALS AND METHODS: Twenty-one patients were administered in a randomized, open, crossover study and received either tropisetron plus dexamethasone or ondansetron plus dexamethasone during two successive cycles of chemotherapy. RESULTS: Control of acute emesis with either tropisetron or ondansetron was 100% vs 95.2%, and 80.9% vs 76.2% in control of delayed emesis. Both severity and duration of nausea showed no statistically significant difference between tropisetron and ondansetron. Poor appetite and headache were most common side effects in both groups. CONCLUSION: There was no significant difference in efficacy for control of emesis and nausea between tropisetron and ondansetron in cisplatin-based chemotherapy.
